PMC:7396557 / 31539-31759
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T170 | 71-82 | CHEBI:100246;CHEBI:100246 | denotes | norfloxacin |
T60157 | 71-82 | CHEBI:100246;CHEBI:100246 | denotes | norfloxacin |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T288 | 107-108 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T265 | 71-82 | Chemical | denotes | norfloxacin | http://purl.obolibrary.org/obo/CHEBI_100246 |
T266 | 124-132 | Chemical | denotes | medicine | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T241 | 0-220 | Sentence | denotes | The results showed that treatment with HXZQP + conventional therapy or norfloxacin tablets was superior to a single Western medicine in terms of total response rate and improvement of clinical symptoms (Yu et al., 2019). |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
885 | 71-82 | Chemical | denotes | norfloxacin | MESH:D009643 |